What NanoMosaic does

NanoMosaic is a privately held biotechnology company headquartered in Waltham, Massachusetts that develops and commercializes an ultrasensitive molecular detection platform built around proprietary Nanoneedle (MosaicNeedle) photonic biosensor arrays — technology exclusively licensed from Harvard University in April 2020. The platform is delivered through the Tessie benchtop instrument paired with Nanoplate consumables (96- and 384-well SBS-standard formats), enabling label-free, simultaneous multi-omic quantification of proteins and nucleic acids from crude biological samples (blood, plasma, serum, CSF, tears, saliva, bioreactor material) with fg/ml sensitivity, 7 orders of dynamic range, 2 µL minimum sample volume, and results in approximately 12 minutes per plate run. Application modules include AAV gene therapy manufacturing QC assays (FDA AMT-designated in January 2026 for multiplex testing of vector genome and capsid titers), full-length transgene and probe walk truncation mapping assays, Tau-PT217/PT181 neurology biomarker assays, and customizable DIY chip configurations.

The company serves gene therapy developers, CDMOs, and pharmaceutical companies (Bristol Myers Squibb, Solid Biosciences, Trisk Bio, Andelyn Biosciences, Catalent) plus leading academic medical centers (Massachusetts General Hospital, New York Stem Cell Foundation, UMass Chan, Brown University). Revenue derives from a hybrid model: Tessie instrument hardware sales, recurring Nanoplate consumables, cloud-based data processing SaaS (21 CFR Part 11-compliant), pre-configured assay kits, and partnership-based companion diagnostic development. Go-to-market is primarily enterprise field sales with a "Request a Demo/Quote" motion, complemented by an Early Access Program, scientific publications, conference presence (ASGCT, AACR, BIO), and co-marketing/channel partnerships with CDMOs and pharma. Total disclosed funding is approximately $45M including a $40.75M Series A led by RA Capital Management (December 2021) plus smaller 2025 SEC exempt offerings, with revenue not publicly disclosed.

Name

NanoMosaic

Legal name

NanoMosaic Inc.

Website

https://nanomosaicllc.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

NanoMosaic develops the FDA AMT-designated Tessie Nanoneedle platform for ultrasensitive, label-free multi-omic analysis of proteins and nucleic acids, serving gene therapy manufacturers, CDMOs, and clinical researchers in neurology and AAV analytics.

Ownership category

akta.pro rank

Product category

Multi-omic Biosensor Instruments

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731), Optical Instruments & Lenses (3827)

akta.pro primary industry

Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA) (HLAAACAK)

akta.pro secondary industries

Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK), Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

Keywords

• Multi-omic biosensors
• Gene therapy analytics
• AAV quality control
• Proteomic diagnostics
• Biomarker detection platforms

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Tessie Instrument Sales: Sale of the Tessie benchtop automated plate reader instrument to research institutions, pharmaceutical companies, gene therapy manufacturers, and hospitals. The instrument performs image acquisition and cloud-based data processing for Nanoplate consumables.
2. Nanoplate Consumables: Recurring revenue from proprietary Nanoplate consumables (96- and 384-well SBS-standard formats) used in the Tessie instrument. Nanoplates are prepared by users with their own capture reagents (antibodies, aptamers) or NanoMosaic-developed assay panels, generating recurring per-run consumable revenue.
3. AAV Gene Therapy Manufacturing QC Assays: Sale of pre-configured assay panels and workflow solutions for AAV bioprocessing and manufacturing QC, including capsid titer, genome titer, full/empty/partial capsid characterization, and truncation mapping assays. Sold as kits or service agreements to gene therapy developers and CDMOs.
4. Cloud-Based Data Analysis Platform: Software-as-a-service revenue from the cloud-based data processing platform that Tessie instruments upload to. Provides automated data analysis, curve fitting, quality control flags, and downstream export capabilities. 21 CFR Part 11-compliant report generation included.
5. Companion Diagnostics Development: Partnership-based revenue from developing companion diagnostic assays with pharmaceutical partners using the Tessie platform, integrating into drug development from clinical trial design through regulatory approval and commercialization.

Go-to-market motion4 records

Distribution channels4 records

Marketing channels7 records

Core offering

NanoMosaic develops and sells the Tessie automated benchtop instrument and Nanoplate consumables, powered by proprietary Nanoneedle (MosaicNeedle) photonic biosensor technology exclusively licensed from Harvard University. The platform enables ultra-sensitive, label-free, multi-omic quantification of proteins, DNA, and RNA from crude biological samples (blood, plasma, serum, tears, CSF, bioreactor material) with fg/ml sensitivity, 7 orders of dynamic range, and 12-minute scan times. Primary applications are AAV gene therapy manufacturing QC (FDA AMT-designated for vector genome and capsid titer testing) and clinical diagnostics including neurological biomarkers.

Product overview

NanoMosaic offers a unified platform architecture centered on its Tessie benchtop instrument and Nanoplate consumables, powered by proprietary Nanoneedle/MosaicNeedle biosensor technology. The platform enables true multi-omic analysis combining protein and nucleic acid quantification in a single run, with approximately 96,000 nanoneedle sensors per well enabling 7 orders of dynamic range from fg/ml sensitivity. Key products include the Tessie instrument and Nanoplate consumables as core components, augmented by application-specific assay modules including AAV Analytics (for gene therapy manufacturing QC), Full-Length Transgene and Probe Walk Assays (for genome integrity mapping), and Tau biomarker assays (for neurological diagnostics). The platform supports end-user DIY customization through open-configuration chips and integrates with liquid handling automation. FDA AMT designation for gene therapy analytics provides regulatory differentiation. The system analyzes crude biological samples (blood, plasma, serum, CSF, tears, saliva) without purification, delivering results in 12 minutes per run.

Differentiator

Problem solved

Functional benefit

Brands

• Tessie™: Flagship benchtop reader platform for multi-omic ultrasensitive quantification of biomolecules (proteins, DNA, and RNA)
• Nanoneedle
• MosaicNeedle™
• Nanoneedle platform

Products and services

• Tessie Benchtop Instrument Fully automated benchtop plate reader instrument that accepts Nanoplate consumables, performs image acquisition and motion control, and uploads data to a cloud-based processing platform. Accepts 96- and 384-well SBS-standard compatible Nanoplates, delivers results in 12 minutes per full plate scan with less than 30 minutes of total hands-on time. Designed for research institutions, pharmaceutical companies, gene therapy developers, CDMOs, and clinical laboratories performing multi-omic quantification.
• Nanoplate Consumables SBS-standard compatible plate consumables in 96- and 384-well formats containing arrays of Nanoneedle (MosaicNeedle) biosensors (approximately 96,000 sensors per well; up to 1.8 billion MosaicNeedles per chip). Users prepare plates with their own capture reagents (antibodies, aptamers, nanobodies, nucleic acids) following an ELISA-like protocol and load as little as 2 µL of crude sample per well. Recurring consumable product for the Tessie instrument enabling fg/ml sensitivity across 7 orders of dynamic range.
• Cloud-Based Data Analysis Platform Cloud-based data analysis software platform that receives uploaded data from Tessie instruments. Includes automated data processing, curve fitting, quality control flags, and exporting capabilities. Provides 21 CFR Part 11-compliant automated report generation for regulated manufacturing and clinical environments. Available as a subscription service bundled with Tessie instrument purchases.
• Proteomics/Multi-Omics Early Access Program Limited-availability program providing life science researchers and CLIA-certified laboratories with access to the Tessie platform for diagnostic test development. Includes system sale, installation, training, and application support. Targets leading research institutions and CLIA-certified labs before full commercial launch, enabling first commercial placements at Massachusetts General Hospital and the New York Stem Cell Foundation.

Quantifiable outcome

• Conventional qPCR/ddPCR can overestimate true full-length AAV genomes by up to ~20-fold compared to NanoMosaic's full-length measurement, because short-region assays count any fragment containing the probed sequence.
• +6 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature10 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Solid BiosciencescoreGTM or Marketing Partner · 2 June 2026Co-marketing agreement pairing Solid's POLARIS-101 next-generation capsid technology with NanoMosaic's FDA AMT-designated Tessie multi-omic analytics platform for gene therapy developers. The partnership aims to provide developers with integrated access to advanced delivery and measurement technologies for improved product characterization, dosing, and regulatory readiness.
• Trisk BiocoreTechnology or Integration · 11 May 2026Partnership integrating NanoMosaic's Tessie analytics platform into Trisk Bio's AAV process workflows in Stevenage, England, and Waltham, Massachusetts. The partnership aims to enhance analytical precision and regulatory compliance for gene therapy manufacturing, embedding Tessie into Trisk's operational workflows across two geographies.
• Bristol Myers Squibb (BMS)coreStrategic or Co-development Partner · 12 February 2025Joint scientific white paper examining how nanoneedle technology can enhance critical quality attribute measurement across AAV manufacturing process development and product quality. BMS and NanoMosaic demonstrated that the nanoneedle technology can effectively quantify AAV subpopulations and distinguish full-length genomes from partial species, offering insights into the production of full-length vectors and addressing limitations in traditional ITR-based titering methods.
• BrickBiocoreStrategic or Co-development Partner · 3 June 2022Partnership to develop a novel site-specific conjugated antibody against phosphorylated Tau (Phospho-Thr217) for the Tessie platform. BrickBio designed a novel antibody using its Site-Select Panel for site-specific, stable conjugation at optimal performance-enhancing sites, specifically for NanoMosaic's CDx neurology panel and future IVD applications.
• UMass Chan Medical SchoolcoreStrategic or Co-development PartnerCollaboration with Sylvain Cecchini's lab at UMass Chan Medical School on AAV gene therapy bioprocessing and manufacturing QC assays. UMass Chan used the Tessie platform to characterize and quantify full, empty, partial, and internally deleted transgenes from crude extracts, presenting findings at ASGCT 2025 and 2026.
• Harvard UniversitycoreTechnology or IntegrationExclusive license to the Nanoneedle technology from Harvard University (Rowland Institute at Harvard), announced April 2, 2020. The technology was developed by Co-Founder Qimin Quan, PhD, and NanoMosaic holds exclusive rights for protein detection and quantification applications.
• New York Stem Cell Foundation (NYSCF)minorStrategic or Co-development PartnerBeta system placement of Tessie at NYSCF Research Institute for wide dynamic range proteomic profiling at various stages of stem cell differentiation. NYSCF leverages the platform to understand proteomic profiles and enhance stem cell research capabilities.

Scale indicators11 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• Cytiva (Danaher): Cytiva provides bioprocessing and analytical instruments, including platforms used in gene therapy manufacturing QC. Broad incumbent serving CDMOs and gene therapy developers with overlapping analytics and process development offerings.
• Bio-Rad Laboratories: Bio-Rad's ddPCR systems are the incumbent standard for AAV genome titer measurement — the very workflow Tessie positions to displace. Broad life-sciences tools incumbent with regulatory and clinical customer relationships overlapping NanoMosaic's gene therapy QC target accounts.
• Bio-Techne (ProteinSimple): Bio-Techne's ProteinSimple portfolio (Simple Western, Ella) and Exosome Diagnostics franchise (acquired for $575M from John Boyce) compete in protein analytics and diagnostics. Established life-sciences tools incumbent with extensive pharma and academic reach.
• Revvity (formerly PerkinElmer Life Sciences): Revvity offers analytical instruments, reagents, and software for life sciences and diagnostics. Provides overlapping immunoassay and analytics platforms for pharma and clinical research customers, including gene therapy analytics workflows.
• 10x Genomics: 10x Genomics offers single-cell and spatial multi-omic platforms. While focused on single-cell genomics, it represents an established incumbent in the broader multi-omics tools market where NanoMosaic competes for proteomics and biomarker discovery budgets.

Direct peers

• Quanterix: Quanterix's Simoa platform is the most direct peer: ultra-sensitive single-molecule protein detection using bead-based immunoassays with fg/ml sensitivity. Competes with NanoMosaic's Tessie for pharma biomarker and proteomics applications, including neurology and AAV analytics workflows.
• SomaLogic: SomaLogic's SomaScan platform performs large-scale proteomic profiling with thousands of aptamer-based measurements per sample. A direct competitor to NanoMosaic's high-multiplex biomarker discovery capabilities, particularly for pharma biomarker and clinical research customers.
• Olink (Thermo Fisher Scientific): Olink's Proximity Extension Assay (PEA) technology enables high-multiplex protein biomarker quantification from small sample volumes. Overlaps with NanoMosaic's biomarker discovery and clinical diagnostics use cases, particularly for pharma companion diagnostic and large-scale proteomics studies.
• Meso Scale Diagnostics (MSD): MSD's electrochemiluminescence-based MULTI-ARRAY and U-PLEX platforms provide high-sensitivity multiplexed immunoassays for biomarker and gene therapy analytics. Established competitor in pharma and academic labs evaluating NanoMosaic's AAV and proteomics offerings.

Emerging players

• Mission Bio: Mission Bio's Tapestri platform performs single-cell multi-omic analysis for cell and gene therapy applications. Emerging player in cell and gene therapy analytics with overlapping target customers and complementary multi-omic value proposition to NanoMosaic's Tessie platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NanoMosaic